Am J Epidemiology Alejandro Szmulewicz Miguel Hernán Co-authors include Gonzalo Martínez-Alés, Dost Öngür, Celso Arango & more.

FEP-CAUSAL Collaboration is an international consortium of prospective cohorts of individuals with first episode psychosis (FEP) that is coordinated by LEAP’s Methods Core.

As psychedelic medicines enter the market, clinicians need informed consent processes tailored to non-research settings. Article describes 7 elements of informed consent to receive psychedelics. ja.ma/3UeMf2Z Mason Marks, MD, JD Rebecca Brendel MD, JD Carmel Shachar I. Glenn Cohen

See my new editorial on Informed Consent to Psychedelic Treatment—A Work in Progress, just out today in JAMA Psychiatry. jamanetwork.com/journals/jamap…

This narrative review describes a new approach to the diagnosis and treatment of psychiatric disorders that is based on dynamical systems theory, which addresses the concepts of tipping points, cycles, and chaos in complex systems. ja.ma/4ahYnG0

In this study of 16,255 adolescents, psychedelic use was significantly associated with more manic symptoms for individuals with a higher genetic vulnerability to schizophrenia or bipolar I disorder than for individuals with a lower genetic vulnerability. ja.ma/48N0gZC

Ken Kendler discusses some new data for old 'vexed questions' - and (as always) makes good sense.
JAMA Psychiatry VCU ISPG PGC Consortium

Are Psychiatric Disorders Brain Diseases?—A New Look at an Old Question

jamanetwork.com/journals/jamap…?

Harvard's McLean Hospital has launched a $2M clinical trial funded by Baszucki Group to test ketogenic therapy for early phase bipolar and schizoaffective disorder.

Chief of McLean's Division of Psychotic Disorders Dr. Dost Öngür, and the lead investigator, Dr. Virginie-Anne

Honored to be elected as the winner of the Pascal-Boyle Prize
europsy.net/pascal-boyle-p…

NEWS FLASH: A clinical trial of #KetogenicTherapy for #Bipolar McLean Hospital is now enrolling!

A$2M gift from baszuckigroup.org will fund an RCT to assess the impact of a #KetoDiet intervention on metabolism & bipolar symptoms.

To enroll, visit bit.ly/3uwmT6B.

As usual Wash U studies probably had it more right than most subsequent work on this!

Hi Kevin! You make valid points about the utility of diagnosis. The challenge is that there are no 'points of rarity' in most measures between these adjacent diagnoses. So any effort that creates neat categories without being curious about the continuity causes information loss

In an editorial, 'Advancing Equity at the JAMA Network,' the editors report on the demographics of JAMA Network editors and editorial board members based on the results of a new survey.

ja.ma/4bwkqJQ

Building a Shared Scientific Understanding of Psychopathology: Q&A with Dost Öngür (Dost Öngür )

The editor of JAMA Psychiatry reflects on the state of psychiatric science

psychiatrymargins.com/p/building-a-s…

JAMA Psychiatry is offering a 2-year editorial fellowship position for a qualified individual who will be supported with a small stipend. Read the editorial. ja.ma/47PVQAB

.JAMA Psychiatry is once again accepting applications for a 2-year Editorial Fellowship. Please share the attached announcement and/or below link with your networks and anyone you think would be a good candidate. cc Dost Öngür Martin Paulus Claudia Lugo-Candelas, PhD (she/ella) -> jamanetwork.com/journals/jamap…

Can machine learning uncover the multivariate neural signature of major depressive disorder in individual patients? This large-scale study including 1,801 patients and controls finds no robust multivariate depression markers. ja.ma/3S0QgFY

🥇Top Viewed in 2023 in JAMA-Psychiatry JAMA Psychiatry Dost Öngür

Evaluation of Brain-Body Health in Individuals With Common Neuropsychiatric Disorders - Ye Ella Tian Ye Ella Tian Andrew Zalesky Andrew Zalesky University of Melbourne & colleagues jamanetwork.com/journals/jamap…

Read the most popular JAMA Psychiatry articles published in 2023. ja.ma/4890daW

Findings suggest that magnetic seizure therapy confers antidepressant benefit while maximizing cognitive safety. ja.ma/46QFqHM

Looking forward to #ACNP2023 and to our session Wednesday morning with Carolyn Rodríguez, MD, PhD Dost Öngür Louise Gallagher Stephanie Ameis & John Krystal. If you're interested in improving clinical trials, via clinical cohorts, biomarkers, EHR & real world data, this one's for you !